Improving shared decision-making around the use of disease modifying anti-rheumatic drugs in patients with rheumatoid arthritis and cancer
Active Project Grant Awarded Last action
- Award ID
- K23AR079588
- Recipient
-
University Of Washington UEI HD1WMN6945W6
- Awarding agency
-
National Insititue of Arthritis and Musculoskeletal and Skin Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $1,486,564
Award facts
- Assistance listing
- 93.846 Arthritis, Musculoskeletal and Skin Diseases Research
- Completion date 86% complete
- Funding
-
- $1,319,785.00 Federal
- $166,779.00 Non-federal
- Place of performance
- Seattle, WA 98195, USA
Award details come from USAspending.gov.
Description
- Abstract
- Over 1.8 million americans have rheumatoid arthritis (RA). Compared to the general population these patients are at an increased risk of developing cancer, especially lymphoma and lung cancer. There has been a theoretical concern that use of immunosuppressive agents may impair immune responses to tumors placing patients at risk for developing new cancers and for recurrence of previously treated cancers. These concerns have made clinicians reluctant to use standard therapies for RA in patients with an active or recently diagnosed cancer. Although only a limited number of studies have evaluated their safety, they have in fact not shown any signal of harm from disease modifying anti-rheumatic drugs (dmards) in patients with RA and cancer. However, these studies have numerous limitations including focus on mostly patients with remote (> 5 years) history of cancer, small sample sizes, focus on only certain dmards, and/or limited information on cancer- specific mortality and other outcomes that might matter to patients. Also, nothing is known about the perspectives and experiences of patients with RA who are being treated for a cancer and how this experience might shape their willingness to use dmards. Treatment guidelines for the management of RA support a shared decision-making (SDM) approach that attempts to leverage the professional expertise of the rheumatologist to uphold what is most important to each patient. We herein propose a mixed methods approach to identify the optimal ways to enhance delivery of care for these patients and to provide a foundation for shared decision making to ensure alignment between treatment decisions and the values, goals, and preferences of individual patients. The studies proposed here will build an evidence base to identify the safest dmard options for patients with RA who develop cancer (aim 1); elicit the experiences, perceptions, and most valued outcomes of patients with RA and an active or recently diagnosed (
Transactions
| Action | Federal | Non-federal | Date |
|---|---|---|---|
| Amendment | $160,131 | $0 | |
| Amendment | $163,014 | $0 | |
| Amendment | $2,000 | $0 | |
| Amendment | $2,000 | $0 | |
| Amendment | $164,617 | $0 | |
| Amendment | $164,617 | $0 | |
| Amendment | $164,924 | $0 | |
| Amendment | $164,924 | $0 | |
| Amendment | $166,779 | $0 | |
| Original award | $166,779 | $166,779 |
Subawards
| Subrecipient | Amount | Awarded |
|---|---|---|
| Veterans Health Administration | $9,364 | |
| Veterans Health Administration | $33,725 |
Quick answers
Who received award K23AR079588?
K23AR079588 was awarded to University Of Washington by National Insititue of Arthritis and Musculoskeletal and Skin Diseases (National Institutes of Health) on July 1, 2022.
How much is award K23AR079588 worth?
$1,486,564 has been obligated on K23AR079588: $1,319,785 in federal funding and $166,779 in non-federal funding.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award